Sihuan Pharmaceutical Holdings Group is developing oral favipiravir (earlier known as jk 05), a small molecule, selective inhibitor of RNA polymerase, for the treatment of COVID-2019 infections. The broad spectrum antiviral was originated by Institute of Microbiology and Epidemiology of the Chinese Academy of Military Medical Sciences and licensed to Sihuan. Chinese media reports state that the government has donated the drug, to fight the 2014 Ebola outbreak in West Africa. After oral absorption, the drug is converted into a bioactive nucleoside triphosphate compound, which is similar to purine, and can compete with purine to inhibit RNA polymerase, inhibiting virus replication. The nucleoside triphosphate compound of Favipiravir can also be inserted into the virus RNA chain and acts as RNA inhibitor by inducing fatal mutation of the virus. Clinical development is underway for COVID-2019 infections in China.
Favipiravir shows anti-Ebola activity and actuivity against other RNA viruses including, influenza, yellow fever, viral haemorrhagic fevers and bunyavirus infections  .
Favipiravir was being developed for Ebola virus infections, however as at November 2017, no recent reports of clinical development had been identified for the development in China.
Favipiravir was being developed for Bunyavirus infections, influenza virus infections, viral haemorrhagic fevers and yellow fever, however as at November 2018, no recent reports of development had been identified for preclinical development in China for these indications.
In October 2014, Beijing Sihuan Pharmaceutical Co Ltd, a subsidiary of the Sihuan Pharmaceutical Holdings Group Ltd, entered into a collaborative development agreement with the Institute of Microbiology and Epidemiology of the Academy of Military Medical Sciences (AMMS), to collaborate for anti-Ebola drug jk-05. Under the terms of the agreement, the Sihuan Pharmaceutical Holdings Group will pay a technology transfer and drug development fee amounting to RMB 10 million to AMMS for the ownership and franchise of the drug. Payment will be settled in installments based on the progress of drug development, until approval for production is received. Sihuan Pharmaceutical Holdings Group and AMMS will support further research and development efforts on jk-05 as a broad-spectrum antiviral drug, and will ensure its manufacture and launch to the market by Beijing Sihuan and addition of the drug to the national reserve. jk-05 is a new drug designated for the treatment of the Ebola virus.
This deal value was converted from RMB at a rate of $US0.163 on 17 October 2014. 
Key Development Milestones
In early February 2020, Sihuan Pharmaceutical Holdings Group initiated clinical trials for favipiravir tablet for COVID-2019 infections.The trials were officially initiated by the Ministry of Science and Technology. The Human Genetic Resources Management Office of the PRC urgently reviewed the Trials and the Group obtained the human genetic resources administrative license in only one working day (2020GH0006YJ). The Trials are random, parallel dose exploration studies with three dosage groups (high, middle and low dosage) to explore the best treatment regimen of Favipiravir for COVID-19 patients. A total of 60 cases of regular COVID-19 patients are planned to be recruited for a treatment period of 10 days  .
Favipiravir received "Army Special Needs Drug Approval" from the People’s Liberation Army General Medical Department in August 2014 and is available for the emergency treatment of Ebola haemorrhagic fever  . Media reports state that doses of the drug have been sent to Africa to fight the 2014 Ebola virus infections, by the Chinese government.